You are here

  • Home
  • Archive
  • Volume 77, Issue 6
  • Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease

Article metrics

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease

 

Online download statistics by month:

Online download statistics by month: February 2018 to March 2024

AbstractFullPdf
Feb 2018383394139
Mar 2018478576200
Apr 201822922980
May 2018659673214
Jun 2018430448126
Jul 201816717361
Aug 201811011039
Sep 2018939536
Oct 201812112138
Nov 2018134150107
Dec 2018858736
Jan 201910510526
Feb 2019879422
Mar 2019939344
Apr 2019918233
May 2019767134
Jun 2019656125
Jul 2019757535
Aug 2019898339
Sep 2019827832
Oct 2019918738
Nov 2019646127
Dec 2019676031
Jan 2020878529
Feb 2020626023
Mar 2020706335
Apr 2020666537
May 2020696468
Jun 20201019266
Jul 2020767233
Aug 2020605234
Sep 2020696827
Oct 202010710051
Nov 2020746939
Dec 2020918533
Jan 2021998741
Feb 2021898630
Mar 202113012081
Apr 2021908540
May 202110910064
Jun 2021747229
Jul 2021948648
Aug 2021807142
Sep 2021726430
Oct 202111510760
Nov 2021776947
Dec 2021928137
Jan 2022938728
Feb 2022635330
Mar 2022897824
Apr 20221049839
May 202210910046
Jun 20221029839
Jul 2022857521
Aug 202213813942
Sep 202210310328
Oct 2022989046
Nov 202211310179
Dec 2022646017
Jan 20231189845
Feb 202312311235
Mar 202311411332
Apr 20231097250
May 20231019053
Jun 2023959230
Jul 2023756534
Aug 20231138956
Sep 2023624824
Oct 202313011236
Nov 2023938328
Dec 20231128250
Jan 2024896841
Feb 20241289146
Mar 2024959055
Total864582963540